Skip to main content

Table 3 The cumulative annual cost - effectiveness and benefit-cost of SIF in Ottawa using the first model

From: A cost-benefit/cost-effectiveness analysis of proposed supervised injection facilities in Ottawa, Canada

Variables Annual cost of operation Sharing rate # of HIV averted # of HCV averted Cost-effectiveness ratio HCV Cost-effectiveness ratio HIV Benefit-cost ratio HCV Benefit-cost ratio HIV Cost-benefit ratio Total
Post SIF $2,182,800 11% 5 48 $45,475 $436,560 0.77 0.48 1.26
   (14%, 7%) (6, 3) (65, 31) ($33,581, $70,413) ($363,800, $727,600) (1.1, 0.5) (0.58, 0.3) (1.63, 0.79)
Two SIF $4,365,600 8% 9 88 $49,609 $485,067 0.71 0.43 1.14
   (11%, 5%) (12, 6) (120, 57) ($36,380, $76,589) ($383,800, $727,600) (1, 0.46) (0.58, 0.3) (1.54, 0.75)
Three SIF $6,548,400 6% 11 112 $58,468 $595,309 0.6 0.35 0.95
   (9%, 4%) (15, 7) (148, 70) ($44,246, $93,549) ($436,560, $936,486) (0.8, 0.38) (0.48, 0.22) (1.28, 0.6)
Four SIF $8,731,200 5% 13 129 $67,683 $671,631 0.52 0.31 0.83
   (7%, 3%) (17, 8) (175, 83) ($49,893, $105,195) ($513,600, $1,091,400) (0.7, 0.33) (0.41, 0.19) (1.11, 0.5)
Five SIF $10,914,000 3% 15 150 $72,760 $727,600 0.48 0.29 0.77
   (5%, 2%) (20, 9) (203, 96) ($53,764, $113,688) ($545,700, $1,212,667) (0.65, 0.31) (0.39, 0.17) (1.04, 0.48)
Six SIF $13,096,800 2% 17 170 $77,040 $770,400 0.46 0.27 0.73
   (3%, 1%) (23, 10) (232, 110) ($569,426, $119,062) ($569,426, $1,309,680) (0.62, 0.3) (0.37, 0.16) (0.99, 0.46)
Seven SIF $15,279,600 1% 19 191 $79,998 $804,189 0.44 0.26 0.70
   (1%, 1%) (26, 12) (259, 123) ($58,995, $124,224) ($587,677, $1,273,300) (0.6, 0.28) (0.36, 0.16) (0.55, 0.45)
  1. Note: The numbers in parentheses represent the results of the sensitivity analysis: (19 per cent sharing rate, 9 percent sharing rate).